{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:56:00Z","timestamp":1791593760990,"version":"4.3.4"},"reference-count":13,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Neurol"],"published-print":{"date-parts":[[2003]]},"abstract":"<jats:p>Therapy with intravenous immunoglobulins (IVIG) is thought to be a safe treatment for a number of immune-mediated neurological diseases. Published data about prevalence of adverse effects range from 11 to 81%. The purpose of our study was to present a representative view on adverse effects by analysis of a large cohort of patients treated by IVIG. In a prospective study, we analysed 117 patients (age 17\u201379 years) who were treated with IVIG for various neurological diseases including chronic inflammatory demyelinating polyneuropathy, diabetic amyotrophy, inclusion body myositis, multiple sclerosis, Guillain-Barr\u00e9 syndrome, Miller-Fisher syndrome, multifocal motor neuropathy, myasthenia gravis and polymyositis. IVIG therapy was applied at a dose of 0.4 g\/kg body weight\/day in a total of 408 therapy courses. 42.7% showed adverse events. The majority of patients presented with minor adverse effects, mostly asymptomatic laboratory changes. Rash or mild headache occurred in 8 patients, especially when IVIG was given with infusion flow higher than 10 g\/h. Two patients showed a severe complication with deep vein thrombosis. In summary, beside its effectiveness in immune mediated neurological diseases, therapy with IVIG seems to be a safe therapy. Most patients show no or minor adverse effects. Patients with pre-existent disorders like heart or renal insufficiency or immobilised patients, however, may be at higher risk for complications.<\/jats:p>","DOI":"10.1159\/000073059","type":"journal-article","created":{"date-parts":[[2003,10,6]],"date-time":"2003-10-06T10:00:52Z","timestamp":1065434452000},"page":"172-175","source":"Crossref","is-referenced-by-count":90,"title":["Therapy with Intravenous Immunoglobulins: Complications and Side-Effects"],"prefix":"10.1159","volume":"50","author":[{"given":"Matthias","family":"Wittstock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Benecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe K.","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2003,10,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901213400311"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5503.481"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(92)90045-P"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1993.1057"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(97)00292-X"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199603)19:3<388::AID-MUS20>3.3.CO;2-Y"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292704"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09377-4"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406233302507"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01167"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(00)00379-8"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199606)19:6<722::AID-MUS6>3.3.CO;2-D"}],"container-title":["European Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/73059","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/73059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:46:42Z","timestamp":1745466402000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000073059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000073059","archive":["Portico"],"relation":{},"ISSN":["0014-3022","1421-9913"],"issn-type":[{"value":"0014-3022","type":"print"},{"value":"1421-9913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003]]}}}